Disclosed are indium (In)-containing film forming compositions comprising In(III)-containing precursors that contain halogens, methods of synthesizing them and methods of using them to deposit the indium-containing films and/or indium-containing alloy film. The disclosed In(III)-containing precursors contain chlorine with nitrogen based ligands. In particular, the disclosed In(III)-containing precursors contains 1 or 2 amidinate ligands, 1 or 2 iminopyrrolidinate ligands, 1 or 2 amido amino alkane ligands, 1 or 2 μ-diketiminate ligands or a silyl amine ligand. The disclosed In(III)-containing precursors are suitable for vapor phase depositions (e.g., ALD, CVD) of the indium-containing films and/or indium-containing alloy films.

An organometallic precursor for extreme ultraviolet (EUV) lithography is provided. An organometallic precursor includes an aromatic di-dentate ligand, a transition metal coordinated to the aromatic di-dentate ligand, and an extreme ultraviolet (EUV) cleavable ligand coordinated to the transition metal. The aromatic di-dentate ligand includes a plurality of pyrazine molecules.

The structure and preparation method of a compound D-L2(-B)-L1-A is disclosed, A is a physiologically and pharmacologically active molecule that physically binds to a specific biological molecule or receptor; L1 is a variable structure with the molecular connection activity at both ends connecting to A and L2; L2 is a variable structure, which has three-terminal molecular connection activity connecting to L1, D and B; B is a physiologically and pharmacologically active molecule that binds to albumin, changing the A molecule in the body cyclic characteristics; D is a polycarboxylic macrocyclic structure that binds to radioisotopes; D-L2(-B)-L1-A compound can be used to express chemokine receptor 4 (CXCR4) receptors on cells, tissues, and/or organs, and after binding with radionuclides, it is suitable for detection of CXCR4 protein binding in vitro, detection of CXCR4 cell binding in vitro or detection of CXCR4 expression in in vivo animal imaging.

A chelate and associated security feature including a lanthanide metal and a ligand of formula (1), formula (2), or formula (3),

##STR00001##

where each of R.sub.1-R.sub.7 in formula (1) is independently selected from the group consisting of H, OH, NH.sub.2, Cl, F, OMe, OAr, OCF.sub.3, CF.sub.3, alkyl, aryl, phenyl, OPh, and heteroaromatic, where each of R.sub.1-R.sub.5 in formula (2) is independently selected from the group consisting of H, OH, NH.sub.2, Cl, F, OMe, OAr, OCF.sub.3, CF.sub.3, NMe.sub.2, CN, alkyl, aryl, phenyl, OPh, and heteroaromatic, and where R.sub.6 in formula (2) is selected from the group consisting of H, NH.sub.2, Cl, F, OMe, OAr, OCF.sub.3, CF.sub.3, NMe.sub.2, CN, alkyl, aryl, phenyl, OPh, and heteroaromatic, and where each of R.sub.1-R.sub.5 in formula (3) is independently selected from the group consisting of H, OH, NH.sub.2, Cl, F, OMe, OAr, OCF.sub.3, CF.sub.3, alkyl, aryl, phenyl, OPh, and heteroaromatic.

The present invention discloses a novel process for the preparation of gadolinium complex of (4S)-4-(4-Ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid disodium of formula 1 and novel intermediates thereof. ##STR00001##

The present invention provides a novel method for preparing high-purity gadobutrol or hydrates thereof. The preparation method of the present invention can have an advantage of simplifying a process by forming a gadolinium complex in-situ without purification of a butrol intermediate and omitting a resin purification process unlike a conventional method for synthesizing gadobutrol. In addition, the preparation method of the present invention can be used to produce high-purity gadobutrol or hydrates thereof at a high yield only through the simple process as above, and thus can be useful in mass production.

A method for treating osteoporosis and related methods are disclosed. The methods generally comprise administering to a patient in need of treatment an effective amount of tris(8-quinolinolato)gallium(III) or an analog thereof.

Metal-organic frameworks (MOFs) comprising amines on the organic linker can be used for cell targeting. In particular, primary amine groups represent one of the most versatile chemical moieties for conjugation to biologically relevant molecules, including antibodies and enzymes. Different chemical conjugation schemes can be used to conjugate biological molecules to the amino functionality on the organic linker. For example, carbodiimide chemistry can be used to link a primary amine to available carboxyl groups on the protein. For example, sulfhydryl crosslinking chemistry can be used via Traut's reagent scheme. As a demonstration of the invention, the ability of EpCAM antibody-targeted MOFs to bind to a human epithelial cell line (A549), a common target for imaging studies, was confirmed with confocal microscopy.

A method of labelling biological molecules with .sup.18F, via attachment of fluorine to a metal complex, where the metal complex is conjugated to the biological molecule. The invention highlights the incorporation of hydrogen bonding (H-bonding) into the metal complex scaffold, and how this can be utilised to improve the kinetics of fluoride incorporation. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.

The present invention relates to the preparation of a series of chiral DOTA, DO3A, DO2A, DO1A, cyclen and their metal complexes, which display properties superior to those of previous DOTA-based compounds, and hence are potentially valuable as a platform for diagnostic applications. The chiral DOTAs reveal a high abundance of twisted square antiprism (TSA) geometry favoring them to be used as potential MRI contrast agents, whereas their rapid labelling properties at mild conditions make them excellent candidates for use as radiometal chelators.